ArticleJHLT open2026
Impact of Impella 5.5 duration support and clinical outcomes in cardiogenic shock: Evidence from a systematic review and meta-analysis of observational studies.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Impella 5.5 is FDA-approved for up to 14 days of support in patients with cardiogenic shock, however, its extended use is increasingly employed as a bridge to advanced therapies. Aim: To compare outcomes with short-term (≤14 days) vs prolonged (>14 days) Impella 5.5 support in patients with cardiogenic shock. Methods: Multiple databases were searched through September 2025 to identify relevant studies, and 5 studies met the inclusion criteria, encompassing total of 1,440 patients. Pooled risk ratios (RRs) with 95% confidence intervals (CI) were calculated using a random-effects meta-analysis in R-software. Results: Prolonged Impella 5.5 support (>14 days) was associated with a higher likelihood of successful bridging to heart transplantation (RR: 1.96, 95% CI: 1.01-3.83; Conclusions: Extending Impella 5.5 support beyond 14 days in patients with cardiogenic shock appears advantageous for select patients, conferring improved survival and higher likelihood of successful bridging to heart transplantation. However, significantly higher risk of implant-site hematoma and infection necessitates meticulous vascular management, infection-prevention strategies and close clinical surveillance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.